Top Story

Nivolumab yields superior OS in NSCLC compared with docetaxel

May 30, 2015

CHICAGO — Nivolumab conferred a 3-month median OS advantage in patients with non-squamous non–small cell lung cancer who progressed on platinum-based doublet chemotherapy compared with docetaxel chemotherapy, according to phase 3 study results presented at the ASCO Annual Meeting.

Patients with high levels of programmed cell death-1 (PD-L1) expression demonstrated the greatest benefit from nivolumab (Opdivo, Bristol-Myers Squibb), results showed.

Meeting News Coverage

Nivolumab shows promise for advanced hepatocellular carcinoma

May 29, 2015
CHICAGO — Nivolumab appeared safe and effective for the treatment of patients with advanced hepatocellular carcinoma, according to interim study results presented…
Tanguy Seiwert, MD Meeting News Coverage

Pembrolizumab demonstrates 'remarkable' efficacy in advanced head and neck cancers

May 29, 2015
CHICAGO — The anti–PD-1 antibody pembrolizumab demonstrated strong activity in patients with recurrent or metastatic head and neck squamous cell carcinoma…
Meeting News CoveragePerspective

Mismatch repair deficiency predicts response to pembrolizumab in several cancer types

May 29, 2015
CHICAGO — Mismatch repair deficiency may be the first genomic marker to predict how patients with cancer will respond to immune checkpoint blockade with the…
Meeting News Coverage

Post-hospital prophylaxis could reduce risk for venous thromboembolism, death after lung resection

May 29, 2015
The incidence of post-operative venous thromboembolism following oncologic lung resections and after discharge is significant, despite guidelines directing prophylaxis…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Melanoma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with melanoma.
More »
Meeting News Coverage Video
VIDEO: Updates in prostate cancer treatment options

VIDEO: Updates in prostate cancer treatment options

May 5, 2015
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, discusses various forms of prostate cancer…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan
morganatic-roan